Tafasitamab (Minjuvi®) – Diffuse large B-cell lymphoma (DLBCL), combination with lenalidomide

Characteristics

Start date 15.09.2021
Resolution 03.03.2022
INN Tafasitamab
Brand name Minjuvi®
Pharm. company Incyte Biosciences Germany
G-BA procedure ID 2021-09-15-D-732
ATC code L01FX12
ICD-10 codes C83.3Diffuse large B-cell lymphoma
DDD 60 mg P
Therapeutic area Oncological diseases ORPHAN
Reason for procedure Initial assessment
Regulatory status Conditional Approval

Indication (German)

MINJUVI is indicated in combination with lenalidomide followed by MINJUVI monotherapy for the

treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who

are not eligible for autologous stem cell transplant (ASCT)

Subpopulation Indication Comparator
Adults with relapsed or refractory diffuse large B-cell lymphoma (DLCBL), for whom autologous stem cell transplantation (ASCT) is not an option – (Orphan drug)

9. Associated procedures



<< List of all resolutions